Literature DB >> 19138237

Withdrawal of inhaled steroids in children with non-cystic fibrosis bronchiectasis.

T Guran1, R Ersu, B Karadag, F Karakoc, G Y Demirel, N Hekim, E Dagli.   

Abstract

BACKGROUND: To study the effects of inhaled steroid withdrawal on bronchial hyperreactivity, sputum inflammatory markers and neutrophilic apoptosis in children with non-cystic fibrosis (non-CF) bronchiectasis.
OBJECTIVES: To evaluate the role of inhaled steroids in the treatment of children with non-CF bronchiectasis with specific emphasis on the bronchial hyperreactivity and neutrophilic apoptosis.
METHODS: Twenty-seven children with steady-state non-CF bronchiectasis were evaluated primarily with metacholine challenge tests and apoptotic neutrophil ratios in induced sputum and secondarily with symptom scores, pulmonary function tests and tumour necrosis factor-alpha (TNF-alpha), interleukin-8 (IL-8) levels and neutrophil ratios in induced sputum before and after 12-week withdrawal of inhaled steroids.
RESULTS: There were 16 girls and 11 boys. Median (interquartile range) age was 11.4 (9.5-13.6) years, follow-up duration was 3.5 (2-6.5) years. Symptom scores (4 vs. 3; P = 0.27), oxygen saturation (95% vs. 97%; P = 0.06), pulmonary function tests (FEV1: 82% predicted vs. 83% predicted; P = 0.73), sputum neutrophil ratios (29.9% vs. 46.8%; P = 0.20), TNF-alpha (58 pg/mL vs. 44.5 pg/mL; P = 0.55) and IL-8 (2.7 ng/mL vs. 2.4 ng/mL; P = 0.82) levels in induced sputum were similar before and after 12-week withdrawal of inhaled steroids. However, the number of patients with bronchial hyperreactivity increased (37% vs. 63% of patients; P = 0.016) and neutrophilic apoptosis in induced sputum decreased (42.8% vs. 20.2%; P = 0.03) after withdrawal.
CONCLUSION: In this study, 12 week-withdrawal of inhaled steroid treatment resulted in a significant increase in bronchial hyperreactivity and decrease in neutrophil apoptosis, but no change in sputum inflammatory markers in children with non-CF bronchiectasis was observed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19138237     DOI: 10.1111/j.1365-2710.2008.00951.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  7 in total

Review 1.  Targeting airway inflammation in cystic fibrosis in children: past, present, and future.

Authors:  Tacjana Pressler
Journal:  Paediatr Drugs       Date:  2011-06-01       Impact factor: 3.022

Review 2.  Bronchiectasis in Children: Current Concepts in Immunology and Microbiology.

Authors:  Susan J Pizzutto; Kim M Hare; John W Upham
Journal:  Front Pediatr       Date:  2017-05-29       Impact factor: 3.418

Review 3.  The Likelihood of Preventing Respiratory Exacerbations in Children and Adolescents with either Chronic Suppurative Lung Disease or Bronchiectasis.

Authors:  Kerry-Ann F O'Grady; Keith Grimwood
Journal:  Front Pediatr       Date:  2017-03-24       Impact factor: 3.418

Review 4.  Short review on the diagnosis and treatment of bronchiectasis.

Authors:  Andrei Lesan; Alicia Elisabeth Lamle
Journal:  Med Pharm Rep       Date:  2019-04-25

Review 5.  Monitoring disease progression in childhood bronchiectasis.

Authors:  Kathryn A Ramsey; André Schultz
Journal:  Front Pediatr       Date:  2022-09-16       Impact factor: 3.569

6.  The immune response and its therapeutic modulation in bronchiectasis.

Authors:  Massoud Daheshia; James D Prahl; Jacob J Carmichael; John S Parrish; Gilbert Seda
Journal:  Pulm Med       Date:  2012-10-10

Review 7.  Inhaled corticosteroids for bronchiectasis.

Authors:  Nitin Kapur; Helen L Petsky; Scott Bell; John Kolbe; Anne B Chang
Journal:  Cochrane Database Syst Rev       Date:  2018-05-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.